By Fineline Cube 
Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic collaboration with China-based GeneQuantum Healthcare. The agreement grants Henlius the development and exclusive commercialization rights for GQ1005, an innovative HER2-targeted antibody-drug conjugate (ADC), in China and certain overseas regions.
Drug Profile
GQ1005 is an innovative HER2-targeted ADC developed by GeneQuantum using its proprietary enzymatic site-specific conjugation technology. The ADC combines a topoisomerase I inhibitor with an anti-HER2 monoclonal antibody via a stable, cleavable ring-opening linker. This design enhances the bystander killing effect while reducing systemic toxicity, balancing efficacy and safety.
Clinical Progress
Currently in Phase III clinical trials for HER2-positive breast cancer, GQ1005 has shown promising anti-tumor activity comparable to trastuzumab deruxtecan in preclinical studies, with a distinct safety advantage.-Fineline Info & Tech